Web Analytics Made Easy - StatCounter
Category

Digestive System Diseases

Association between cannabis use and complications related to ulcerative colitis in hospitalized patients: A propensity matched retrospective cohort study.

By | Colitis, Digestive System Diseases

Authors: Chimezie Mbachi, Bashar Attar, Olamide Oyenubi, Wang Yuchen, Aisien Efesomwan, et al
Medicine, August 2019

Ulcerative colitis (UC) is a chronic inflammatory process that is occasionally associated with complications that cause significant morbidity and mortality. Studies in experimental animal models have demonstrated a beneficial effect of cannabis on intestinal inflammation. It i…

Read More

Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes.

By | Anorexia, Behavioral Health, Brain Disorders, Clinical Endocannabinoid Deficiency, Digestive System Diseases, Headache Disorders, Immune System Diseases , Irritable Bowel Syndrome, Multiple Sclerosis, Nervous System Diseases, Parkinsonian Disorders, Stress Disorders - Post-Traumatic

Authors: Ethan B. Russo
Cannabis and Cannabinoid Research, 1 July 2016

Medicine continues to struggle in its approaches to numerous common subjective pain syndromes that lack objective signs and remain treatment resistant. Foremost among these are migraine, fibromyalgia, and irritable bowel syndrome, disorders that may overlap in their affected p…

Read More

Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study.

By | Crohn Disease, Digestive System Diseases

Authors: Timna Naftali, Timna Naftali, Lihi Bar-Lev Schleider, Iris Dotan, Ephraim Philip Lansky, et al
Clinical Gastroenterology and Hepatology, October 2013

BACKGROUND & AIMS: The marijuana plant Cannabis sativa has been reported to produce beneficial effects for patients with inflammatory bowel diseases, but this has not been investigated in controlled trials. We performed a prospective trial to determine whether cannabis can ind…

Read More

Cannabis use amongst patients with inflammatory bowel disease.

By | Colitis, Crohn Disease, Digestive System Diseases

Authors: Simon Lal, Neeraj Prasad, Manijeh Ryan, Sabrena Tangri, Mark Silverberg, et al
European Journal of Gastroenterology & Hepatology, October 2011

BACKGROUND: Experimental evidence suggests the endogenous cannabinoid system may protect against colonic inflammation, leading to the possibility that activation of this system may have a therapeutic role in inflammatory bowel disease (IBD). Medicinal use of cannabis for chron…

Read More

Treatment of Crohn’s disease with cannabis: an observational study.

By | Crohn Disease, Digestive System Diseases

Authors: T. Naftali, L. Bar Lev, D. Yablekovitz, E. Half, F.M. Konikoff
Israel Medical Association Journal, August 2011

BACKGROUND: The marijuana plant cannabis is known to have therapeutic effects, including improvement of inflammatory processes. However, no report of patients using cannabis for Crohn’s disease (CD) was ever published. OBJECTIVES: To describe the effects of cannabis use in pat…

Read More

Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis.

By | Colitis, Digestive System Diseases

Authors: Francesca Borrelli, Gabriella Aviello, Barbara Romano, Pierangelo Orlando, et al
Journal of Molecular Medicine, November 2009

Inflammatory bowel disease affects millions of individuals; nevertheless, pharmacological treatment is disappointingly unsatisfactory. Cannabidiol, a safe and non-psychotropic ingredient of marijuana, exerts pharmacological effects (e.g., antioxidant) and mechanisms (e.g., inh…

Read More

Cannabinoid hyperemesis syndrome: clinical diagnosis of an underrecognised manifestation of chronic cannabis abuse.

By | Cannabinoid Hyperemesis Syndrome, Digestive System Diseases, Esophagitis

Authors: Siva P. Sontineni, Sanjay Chaudhary, Vijaya Sontineni, Stephen J. Lanspa
World Journal of Gastroenterology, 14 March 2009

Cannabis is a common drug of abuse that is associated with various long-term and short-term adverse effects. The nature of its association with vomiting after chronic abuse is obscure and is underrecognised by clinicians. In some patients this vomiting can take on a pattern si…

Read More

Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

By | Brain Disorders, Clinical Endocannabinoid Deficiency, Digestive System Diseases, Headache Disorders, Irritable Bowel Syndrome, Medical Cannabis, Muscular Diseases, Nervous System Diseases

Authors: Ethan Budd Russo
Neuroendocrinology Letters, April 2008

OBJECTIVES: This study examines the concept of clinical endocannabinoid deficiency (CECD), and the prospect that it could underlie the pathophysiology of migraine, fibromyalgia, irritable bowel syndrome, and other functional conditions alleviated by clinical cannabis. METHODS:…

Read More

Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease.

By | Digestive System Diseases, Liver Diseases, Skin Diseases

Authors: Guy Neff, Christopher O’Brien, Rajender Reddy, Nora Bergasa, Arie Regev, et al
The American Journal of Gastroenterology, August 2002

Pruritus due to cholestatic liver disease can be particularly difficult to manage and frequently is intractable to a variety of medical therapies. The aim of our study is to evaluate the efficacy of delta-9-tetrahydrocannabinol (delta-9-THC) for intractable cholestatic related…

Read More